Summary of Financial Results for the second quarter 2023
  • 2022/11/14
サブ-ナビゲーション
  • 【リダイレクト】
  • HOME
  • 現在位置:News Release
  • Company
    • Basic Philosophy
    • Top Message
    • Corporate Governance
    • Business Activities
    • Company Outline
      • Board of Directors and Executive Officers
      • History
    • Office Locations
    • Affiliate Companies
  • Sustainability
    • Environmental Initiatives
    • Procurement Initiatives
    • Diversity Initiatives
    • Community Initiatives
    • Human Rights Initiatives
    • Sustainability Promotion Framework
  • Business Activities
    • Products
      • Gelatin
      • Collagen Peptide
        • Wellnex® DI-PEPTIDE
        • Wellnex® standard type
      • Food Material
      • Biomedical
    • Market/Application
      • Health Support
      • Biomedical
        • Cellmatrix
          • How to choose Cellmatrix Type I products
        • beMatrix
        • LET Gelatin
        • MedGel II
        • Other Products Line-up
        • Basic Knowledge
        • About Us
          • Wellcome
        • Brochure, Reference & Manual
          • Brochure & Reference
          • Safety Data Sheet
        • FAQ
  • Investor Relations
    • Corporate Governance
    • Financial Information
      • Financial Highlight (Full Year)
      • Financial Indicator (Consolidated)
    • IR Library
      • Earnings Reports
      • Annual Reports
      • Presentation
    • Disclosure Policy
    • IR Contact
  • Access
  • Web Institute
    • Biomedical Lab.
      • 01. Living with the Cells
      • 02. Expansion to medical field
      • 03. Medical applications related to collagen and gelatin
    • Peptide Lab.
      • 01. Basic Knowledge
      • 02. Absorption
      • 03. Skin
        • 03. Skin (Clinical Trial)
        • 03. Skin (Mechanism 1)
        • 03. Skin (Mechanism 2)
      • 04. Pressure Ulcer
        • 04. Pressure Ulcer (Clinical Trial)
        • 04. Pressure Ulcer (Mechanism)
      • 05. Blood Vessel
      • 06. Bone
      • 07. Blood Sugar
      • 08. Muscle
      • 09. Joint
        • 09. Joint (Clinical Trial)
        • 09. Joint (Animal Studies)
        • 09. Joint (Mechanism)
      • 10. Video Library
  • Basic Information Security Policy
  • Privacy Policy
  • Cookie Policy
  • Basic Social Media Policy
    • Social Media Terms of Service
  • Contact Us
    • Corporate Contact
    • Biomedical Contact
  • Contact Us

Summary of Financial Results for the second quarter 2023

  • 2022/11/14

News Release

Company

Basic Philosophy

Top Message

Corporate Governance

Business Activities

Company Outline

Office Locations

Affiliate Companies

Sustainability

Environmental Initiatives

Procurement Initiatives

Diversity Initiatives

Community Initiatives

Human Rights Initiatives

Sustainability Promotion Framework

Business Activities

Products

Market / Application

Investor Relations

Corporate Governance

Financial Information

IR Library

Disclosure Policy

IR Contact

  • 日本語
  • English
  • 中文
  • Access

ページの先頭へ

News Release

Company

Basic Philosophy

Top Message

Corporate Governance

Business Activities

Company Outline

  • Board of Directors and Executive Officers
  • History

Office Locations

Affiliate Companies

Sustainability

Environmental Initiatives

Procurement Initiatives

Diversity Initiatives

Community Initiatives

Human Rights Initiatives

Sustainability Promotion Framework

Business Activities

Products

Market / Application

Investor Relations

Corporate Governance

Financial Information

  • Financial Highlight (Full Year)
  • Financial Indicator (Consolidated)

IR Library

  • Earnings Reports
  • Annual Reports
  • Presentation

Disclosure Policy

IR Contact

  • Contact Us
  • Basic Information Security Policy
  • Privacy Policy
  • Cookie Policy
  • Basic Social Media Policy
  • Access

© Nitta Gelatin Inc. All rights reserved